

# AgraFlora Organics International Inc.

08:23 03 Jan 2020

## AgraFlora Organics completes acquisition of Germany's Good Company

AgraFlora Organics International Inc (CSE:AGRA) (OTCMKTS:AGFAF) said Friday it has closed the acquisition of 100% of the issued and outstanding shares of Germany's The Good Company GmbH.

On October 25, the Vancouver-based company acquired The Good Company, the parent company of German medical cannabis distributor, Farmako GmbH.

Farmako is a leading European medical cannabis distributor, headquartered in Frankfurt, with affiliated companies in the United Kingdom, Luxembourg and Denmark. Farmako has a distribution network of 19,800 pharmacies covering 100,000 patients.

**READ:** AgraFlora Organics to design onsite farm-gate retail facilities at its Ontario operations

In a statement, AgraFlora Organics CEO Brandon Boddy said the combined entity will be equipped with "world-class" upstream cultivation assets, as well as efficient European downstream capabilities that will "act as a beachhead" into the 700-million-person European marketplace.

"It will crystallize a defendable advantage within the edibles, cannabinoid-infused beverage and product formulation market verticals," said Boddy.

"Farmako's prestigious good distribution practice certification marks the highest standards of medical cannabis distribution in the world, permitting the bulk warehousing of medical cannabis on German soil, allowing for direct sales into an underserved marketplace," he added.

Boddy said the acquisition solidified AgraFlora as a global cannabis leader and further reinforced the firm's vertical integration.

### Key licences in Germany

The company said Farmako has "unparalleled access" to Germany's growing medical cannabis marketplace as it has a medical wholesale distribution licence under the German Medicines Act. It also has a permit for narcotic drug handling issued by German Betaubungsmittelgesetz.

Most significantly, Farmako hauled in revenues of over \$2,750,000 in the 2019 fiscal year and has captured 8% share of Germany's medical cannabis market, said the company.


According to market data from Insight Health, a German patient is prescribed approximately 30 grams of medical cannabis per month. When extrapolated, this equates to annualized cannabis demand of 36 tons, pointed out the company, while noting that the country represented the "largest consumer base" for cannabis in the European Union.

Patients enjoy full reimbursement of 60% of all medical/pharmaceutical cannabis prescriptions, said the company.

**Price:** 0.05

**Market Cap:** \$21.85 m

### 1 Year Share Price Graph



April 2019    October 2019    April 2020

### Share Information

**Code:** AGRA

**Listing:** CSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	0.63	0.03

**Sector:** Cannabis

**Website:** agraflo.com

### Company Synopsis:

*AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. The Company is a vertically integrated with significant cultivation, manufacturing, branding and distribution capabilities. Its flagship asset is a joint venture in a large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC, currently being retrofitted for cannabis production.*

action@proactiveinvestors.com

The German medicinal cannabis market can be divided into two principal submarkets. The pharmaceutical cannabis market consists of cannabis-based drugs like Sativex, Dronabinol and Nabilone, while the medical cannabis market consists of plant-based cannabis products.

### **Progress in the UK market**

AgraFlora's UK subsidiary, Farmako Ltd, has completed its UK Home Office inspection for the purpose of obtaining a controlled drug licence.

In 2019, Farmako Ltd received authorization for the wholesale distribution of medicinal products, including medical cannabis after completing a successful inspection by UK's Medicines and Healthcare Products Regulatory Agency, said the company.

The UK medicinal cannabis market is forecast to touch \$1.3 billion by 2024. Prohibition Partners estimates that up to 1% of the UK population could qualify as medical cannabis patients by 2028.

"Initially, Farmako Ltd will pursue the import of Bedrocan products from the Netherlands to the UK for end-patient distribution," said the company.

Within the UK, medical/pharmaceutical cannabis can be prescribed by physicians for multiple sclerosis, chemotherapy-induced nausea, severe treatment-resistant epilepsy in children, chronic pain in adults and appetite and weight loss associated with HIV/AIDS.

Prohibition Partners estimates that there are as many as 3.6 million active cannabis users in the UK.

AgraFlora is based in Vancouver and owns an indoor cultivation facility in London, Ontario, as well as an edibles manufacturing facility in Winnipeg, currently being retrofitted. The company is also a joint venture partner in Propagation Services Canada Inc, which operates a 2.2 million-square-foot greenhouse complex in Delta, British Columbia.

Contact the author Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: @UttaraProactive

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### **No investment advice**

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as

providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of AgraFlora Organics International Inc. named herein, including the promotion by the Company of AgraFlora Organics International Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).